"Seattle Times": Pangu Technology's clinical experiments seriously violate medical regulations. It took less than half a year from the emergence of their technology to the final clinical treatment. This not only violates the international clinical experimental rules on the treatment of malignant tumors, but also violates Xia Guo's own clinical experimental rules. We have reason to suspect that Pangu Technology's clinical experiments are just simple procedures, and we have reason to suspect that Pangu Technology's technology comes from the United States.

"New York Times": The New York court accepted the infringement case of Pangu Technology's suppression gene expression therapy in Pangu Technology. Bristol Squibb has provided quite sufficient evidence. If Pangu Technology does not respond to the lawsuit, the court will be tried in absentia. In addition, Squibb also appealed to more than 20 international intellectual property organizations and asked relevant departments of Xiaguo to face up to Squibb's demands and stop the treatment qualifications of Pangu Technology's related technologies.

After the news of the New York Times came out, many Western media rushed to report it.

Several well-known medical institutes including Stanford University's Institute of Molecular Medicine, Mayo Clinic, Mofid Cancer Center and the Institute have paid attention to the progress of things.

They expressed their doubts after Pangu Technology's paper came out, and they even doubted the authenticity of the paper "Gene Expression" published in the Cell journal.

At the same time, the United States FDA also formally issued an investigation notice to Pangu Technology. The reason why FDA suspected Pangu Technology was that the patient's physical indicators before and after treatment, as well as the treatment methods and methods of nivolumab after treatment were similar.

Gao Siqi took the FDA's investigation notice and came to Xiao Ming's office and said, "The Americans are going crazy!"

Qian Yi, who was talking to Xiao Ming, looked at the investigation notice and said, "What are they thinking? Pangu Technology has no business in the United States. Can a US department investigate Xia Guo's company?"

Gao Siqi said: "Squibb's nivolumab has been banned from sale worldwide, and FDA also requires us to stop gene suppression."

Qian Yi asked strangely: "Navulumab is stopped selling globally? Then isn't Squibb's company suffering serious losses?"

Xiao Ming knew what Gao Siqi wanted to express, and he said: "FDA and more than 20 intellectual property organizations around the world initiated an investigation into us should not only be Squibb's separate actions, but also the actions of the entire American medical community. Squibb lost a nivolumab sales that had just been listed in exchange for Xia Guo's loss of a treatment method that changed the global medical industry. This deal is quite cost-effective!"

Gao Siqi also added: "Now I understand the calculations of the US company. Squibb has many cancer targeted drugs. Even if nivolumab is not sold for the time being, there are still many alternative cancer-like targeted drugs, which have almost no loss of their profits. What is lost is the patient's survival chance. Even if cancer patients cannot buy nivolumab, they will buy other drugs from Squibb. However, what Pangu Technology and the entire China have lost is the opportunity to inhibit the development of gene therapy."

Qian Yi asked: "These pharmaceutical companies and medical departments in the United States are so bloody? Do they care about the chances of patients' survival?"

Xiao Ming smiled and said, "Bloody? Which pharmaceutical company does not make a fortune by relying on blood? In the United States, cancer only has life expectancy and no 100% successful treatment. As long as the interests are not damaged, it is no difference for these pharmaceutical companies to die early and late."

Gao Siqi said: "According to the agreements of multiple intellectual property organizations, the relevant departments of Xia Kingdom should respond to them. Anyway, we Pangu Technology will not respond to any response. We are afraid that we will not be able to explain the war of verbalism with the United States for several years."

"The news is coming." Qian Yi said while browsing her phone.

On Weibo, Xia Guo’s media have spoken out about FDA’s notice. In addition to harsh refutations, they also accused the US laws of not being able to govern Xia Guo’s enterprises.

Qian Yi handed the phone to Xiao Ming.

In addition to Xia Guo media's refutation of the FDA notice, many netizens are also speaking out for Pangu Technology.

"The Americans are so disgusting! How to use American laws to require Xia Guo's company."

"We don't use the US operating system, why are we still saying that we infringe on intellectual property rights?"

"Just you can't stand us, okay?"

"We must say that we infringe on intellectual property rights! The imported targeted drugs cost tens of thousands of yuan a month, and all of our technologies can be cured if they are 300,000 to 400,000 yuan. Is there any way for these American pharmaceutical companies?"

Jiangcheng University Affiliated Hospital has also spoken out for Pangu Technology. In the announcement of the affiliated hospital, more than a dozen oncology experts said: "Pangu Technology has independent and independent intellectual property rights and is a new generation of nausea tumor therapy that is advanced in targeted therapy. Jiangcheng University will not stop using this technology to treat patients."

After reading the news, Xiao Ming said: "Pangu Technology will be solved by Pangu Technology itself. We must learn to deal with Westerners from this matter."

Xiao Ming arranged a task for Gao Siqi and said, "Don't worry about anything, follow the plan. We have no business in the United States, so we will not be afraid of any investigation and trial. Also, if Xia Guo really accepts the conditions of the United States and prohibits the use of inhibitory gene therapy in the medical field of Xia Guo, then I think Pangu Group can move as well."

What Xiao Ming said was very serious. This incident was a test for Pangu's technology and a test for Xia Guo's technical confidence.

However, with Xiao Ming's instructions, Gao Siqi was able to carry out her work boldly.

The first is to increase the production capacity of inhibitors, and the second is to cooperate with Jiangcheng University Affiliated Hospital to expand the treatment of patients.

Xiao Ming also agreed with Jiangda Affiliated Hospital. After the full number of patients in Jiangda Affiliated Hospital, it will spread out with Jiangda Affiliated Hospital as the center, and send technicians to other Grade A hospitals so that patients across the country can receive treatment at their doorsteps.

The Affiliated Hospital of Jiangcheng University also stated that it will actively communicate with superior departments and strive to not implement the technical ban.

Many patients were very panicked after seeing reports from foreign media and seeing various news on the Internet. If the treatment of inhibiting gene expression is really prohibited, what should the patients do?

Many people left messages under Pangu Technology to ask for the latest news.

"Why do Americans manage our Xia Kingdom patients!"

"Don't ban it! I just registered for my father!"

"If joining the International Intellectual Property Organization has such an impact on Xia Guo, why should we join?"

Regarding the patients’ questions, Pangu Technology responded uniformly: "We will not give up any patient." m.
Chapter completed!